Welcome to our dedicated page for PERKINELMER news (Ticker: PKI), a resource for investors and traders seeking the latest updates and insights on PERKINELMER stock.
PerkinElmer Inc. (PKI) drives innovation in diagnostics, life sciences, and applied markets through advanced scientific solutions. This page aggregates official announcements and verified news about the company's strategic initiatives, financial performance, and technological advancements.
Investors and industry professionals will find timely updates on earnings reports, product launches, and regulatory milestones. Our curated collection simplifies tracking PKI's progress in enabling critical research and improving healthcare outcomes globally.
Key content includes updates on analytical instrumentation developments, partnership announcements with research institutions, and expansions in diagnostic testing capabilities. All materials adhere to strict factual reporting standards without speculative commentary.
Bookmark this page for streamlined access to PerkinElmer's latest corporate communications. Check back regularly for insights into how PKI continues to address complex challenges in scientific discovery and clinical diagnostics.
PerkinElmer, Inc. (NYSE: PKI) announced it will release its third quarter 2021 financial results on November 2, 2021, after market close. The company will host a conference call at 5:00 p.m. ET to discuss the results, featuring CEO Prahlad Singh and CFO Jamey Mock. Investors can access a live audio webcast via the company’s website. A replay of the call will be available after 7:00 p.m. ET on the same day. PerkinElmer reported approximately $3.8 billion in revenue for 2020 and aims to innovate for a healthier world.
PerkinElmer, NYSE:PKI, has received Emergency Use Authorization (EUA) from the FDA for its PKamp Respiratory SARS-CoV-2 RT-PCR Panel 1. This test allows labs to simultaneously detect and differentiate between SARS-CoV-2, influenza A, influenza B, and RSV from respiratory samples. The test aims to streamline testing during the flu season, helping to alleviate confusion from similar symptoms. PerkinElmer's existing CE marking for this test in over 30 countries is also noted. The company reported revenues of approximately $3.8 billion in 2020.
PerkinElmer has received Emergency Use Authorization (EUA) from the U.S. FDA for its Anti-SARS-CoV-2 S1 Curve ELISA (IgG). This assay enables the qualitative and semi-quantitative detection of IgG antibodies against the SARS-CoV-2 S1 antigen in human serum and plasma. It is designed for use by CLIA-certified laboratories and plays a critical role in vaccine development and research on immunity. The assay can be used manually or on various ELISA platforms, enhancing laboratory capabilities in understanding COVID-19 immunity.
PerkinElmer, Inc. (NYSE: PKI) has successfully completed its acquisition of BioLegend for approximately $5.25 billion. This strategic move represents the largest acquisition in PerkinElmer's history, expanding its life science offerings into high-growth sectors such as cytometry and proteogenomics. BioLegend is projected to enhance PerkinElmer's revenue by $380 million and contribute $0.30 to adjusted earnings per share in fiscal year 2022. The integration aims to bolster innovation in therapeutic discovery and improve the overall reagents portfolio.
PerkinElmer (NYSE: PKI) announced the pricing of a total of
PerkinElmer, Inc. (NYSE: PKI) will present at the Baird Global Healthcare Conference on September 14, 2021, at 10:50 a.m. ET. During the virtual event, Steve Willoughby, Vice President of Investor Relations, will discuss the company's strategic priorities. A live audio webcast can be accessed in the Investors section of the company's website, with a replay available for 90 days post-event. PerkinElmer reported approximately $3.8 billion in revenue in 2020 and has over 14,000 employees worldwide.
PerkinElmer reported robust financial results for Q2 2021, with GAAP EPS of $2.19, up from $1.23 in Q2 2020. Revenue surged to $1.228 billion from $812 million, reflecting a growth rate of 51%. Operating income also rose significantly to $332 million, yielding an operating profit margin of 27.1%. The company announced an acquisition of BioLegend for $5.25 billion and raised its full-year guidance to $4.57 billion in revenue and $9.88 in EPS. The acquisition is expected to enhance its market position.
PerkinElmer (NYSE: PKI) has announced an agreement to acquire BioLegend for approximately $5.25 billion in cash and stock, marking the largest transaction in PerkinElmer’s history. This strategic acquisition aims to enhance PerkinElmer’s life science offerings, particularly in high-growth areas like proteogenomics and cell separation. BioLegend is expected to generate around $380 million in revenue for 2022 and will transition into PerkinElmer’s Center of Excellence for research reagents. The deal anticipates earnings accretion of $0.30 per share in the first year.
PerkinElmer, Inc. (NYSE: PKI) announced a quarterly dividend of $0.07 per share on July 23, 2021. The dividend is scheduled for payment on November 12, 2021, to shareholders of record as of October 22, 2021. PerkinElmer reported a revenue of approximately $3.8 billion in 2020 and employs around 14,000 people across 190 countries. The company is also included in the S&P 500 Index.
PerkinElmer (NYSE: PKI) announced it expects to exceed its financial guidance for Q2 ending July 4, 2021, driven by strong performance in both COVID and non-COVID sectors. A Virtual Investor and Analyst Day is set for today, featuring presentations from key executives. The company will release its Q2 financial results after market close on July 28, followed by a conference call at 5:00 p.m. ET the same day. In 2020, PerkinElmer reported approximately $3.8 billion in revenue and employs over 14,000 people globally.
FAQ
What is the market cap of PERKINELMER (PKI)?
